Cabozantinib promotes erythroid differentiation in K562 erythroleukemia cells through global changes in gene expression and JNK activation

Fu, YH; Ou, DL; Yang, YR; Su, KW; Chen, CY; Tien, HF; Lai, ZS; Shen, CKJ; Chien, HF; Lin, LI

Lin, LI (通讯作者)，Natl Taiwan Univ, Dept Clin Lab Sci & Med Biotechnol, Taipei, Taiwan.;Chien, HF (通讯作者)，Taipei Med Univ Hosp, Dept Surg, Div Plast Surg, Taipei, Taiwan.;Chien, HF (通讯作者)，Taipei Med Univ, TMU Ctr Cell Therapy & Regenerat Med, Taipei, Taiwan.;Lin, LI (通讯作者)，Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan.

CANCER GENE THERAPY, 2022; 29 (6): 784

Abstract

Cabozantinib is a potent tyrosine kinase inhibitor with multiple targets including MET, VEGFR2, RET, KIT, and FLT3. Cabozantinib is widely used for th......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索